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article under the CC BY-NC-ND licenseAbstract Objective: Recent reports on high-intensity focused ultrasound (HIFU) treatment of
localized prostate cancer suggest that preoperative risk groups of tumor recurrence are strong
predictors of oncological outcomes. The purpose of this study is to determine the prognostic
significance of treatment-related factors in relation to patient characteristics for biochemical
outcomes after HIFU.
Methods: This retrospective single-center study included patients treated from December
2002 to December 2010 for localized prostate cancer with two generations of Ablatherm HIFU
devices (A1 and A2). All the patients underwent single HIFU treatment session under the
concept of whole-gland therapy. Prostate surgery was performed before HIFU to downsize
enlarged glands. Androgen deprivation therapy (ADT) was discontinued before HIFU. Biochem-
ical failure (BCF) was defined as prostate specific antigen (PSA) nadir þ 1.2 ng/mL (Stuttgart
definition). Predictors of BCF were determined using Cox regression models. As covariates,
patient-related factors (age, tumor characteristics, ADT) were compared with treatment-
related factors (prostate volume, HIFU device generation, conduct of therapy, prostate
edema, patient movement, anesthetic modalities).
Results: Three hundred and twenty-three (98.8%) out of 327 consecutive patients were evalu-
able for BCF. Median (interquartile range) follow-up was 51.2 (36.6e80.4) months. The overall
BCF-rate was 23.8%. In multivariate analyses, higher initial PSA-values (Hazard ratio [HR]: 1.03;
p < 0.001) and higher D’Amico risk stages (HR: 3.45; p < 0.001) were patient-related predictors
of BCF. Regarding treatment-related factors, the A2 HIFU device was associated with a
decreased risk of BCF (HR: 0.51; p Z 0.007), while prostate edema had an adverse effectos.com (D. Pfeiffer).
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HIFU: treatment-related predictors of biochemical outcomes 47(HR: 1.8; p Z 0.027). Short follow-up and retrospective study design are the primary limita-
tions.
Conclusion: Success in a single HIFU session depends not merely on tumor characteristics, but
also on treatment-related factors. Ablation is more efficacious with the technically advanced
A2 HIFU device. Heat-induced prostate edema might adversely affect the outcome.
ª 2015 Editorial Office of Asian Journal of Urology. Production and hosting by Elsevier
(Singapore) Pte Ltd. This is an open access article under the CC BY-NC-ND license (http://
creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
High-intensity focused ultrasound (HIFU) is a non-surgical,
minimal invasive procedure that enables ablation of the
prostate in situ. Extensive experience in treating clinically
localized prostate cancer (PCa) has been gained using
Ablatherm HIFU devices (EDAP-TMS, Vaulx-en-Velin,
France). The curative potential was already recognized in
1996 with the use of a prototype [1]. Since then, the
oncologic efficacy has been evaluated with two commer-
cially available devices. Recently, oncologic outcomes have
been reported from large studies [2e4]. All reports
demonstrate that the efficacy of HIFU treatment is associ-
ated with the risk stages of tumor recurrence [5], which
illustrates the strong influence of preoperative tumor
characteristics.
By contrast, the impact of treatment-related factors on
cancer control is not well documented.
The principles of a complete prostate ablation (whole-
gland therapy) as a prerequisite of complete tumor eradi-
cation have been delineated recently [6,7]. Whether the
evolving HIFU technology is associated with improving
outcomes in patients treated under these principles has still
to be determined [2]. Moreover, variations in planning and
conducting whole-gland therapy might affect the out-
comes. In addition, intraoperative prostate edema or un-
intentional patient movements might interfere with the
treatment plan and influence the results of therapy.
The present retrospective single-center study reports on
biochemical outcomes after whole-gland treatment of
localized PCa involving two generations of Ablatherm HIFU
devices. We focused on the efficacy of a single HIFU
application and determined whether treatment-related
factors (prostate volume, HIFU device generation,
conduct of treatment, prostate edema, patient movement,
anesthetic modalities) have prognostic significance as
outcome predictors independent of preoperative patient
characteristics.2. Methods
2.1. Patients
The records of all patients with clinically localized PCa who
underwent a single session of whole-gland HIFU treatment
as a first-line therapy with curative intent between
December 2002 and December 2010 were assessed retro-
spectively. All men were unsuitable candidates for radical
prostatectomy because of age or comorbidity and wereunwilling to undergo radiotherapy. Extracapsular tumor
extension and lymph node status was assessed with pelvic
CT or MRI. Staging included a bone scan in patients with
prostate specific antigen (PSA) 10 ng/mL, and laparo-
scopic lymphadenectomy was recommended in patients
with PSA >20 ng/mL. Androgen deprivation therapy (ADT)
was discontinued at the time of HIFU therapy.
Excluded from the study were patients with nerve-
sparing HIFU ablation (preserving the neurovascular bun-
dles by sparing the lateral prostate regions [8]), and pa-
tients with nodal extension or metastatic disease.
2.2. HIFU technology
Treatment involved two generations of Ablatherm de-
vices, the Ablatherm Maxis and Ablatherm Integrated
Imaging (after February 2006), hereafter addressed
respectively as device A1 and A2. Both devices comprised a
3 MHz therapeutic and a 7.5 MHz imaging transducer. The
treatment transducer generates a focused ultrasound field
and creates spindle-shaped elementary lesions of 1.7 mm in
diameter by heat (85e100 C) and cavitation. By variable
focusing, the focal length is adjustable (19e26 mm)
together with the rectum distance length (3e8 mm). The
maximum penetration depth in prostatic tissue is limited to
30 mm [3]. The treatment-head moves computer-driven
and larger target volumes can be ablated through
repeated shots in juxtapositions. With the more advanced
A2 device a new electronic probe with optimized treatment
parameters was introduced which allows direct visual
control of the procedure via transrectal ultrasound (TRUS)
[9]. Local movements of the applicator system were
reduced, thus providing a more accurate targeting of the
prostate [10].
2.3. Standard planning and conduct of treatment
The intention of whole-gland therapy is destruction of the
prostate with a safety margin of 6 mm from the apex to
preserve the urethral sphincter. The ablation technique
should avoid leaving gaps of untreated tissue at prostate
margins and within the gland [6]. In patients at risk of
extracapsular tumor extension, the treatment can be
extended by millimeters beyond the lateral organ
boundaries [7]. A safety margin of at least 3 mm is
maintained around the rectum. In patients with enlarged
prostate glands, prostate surgery is performed prior to
HIFU in order to ensure that the anterior prostate margins
are within the limited spatial span of the ultrasound
focus [3].
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several cranio-caudal blocks which are planned and treated
separately [7]. Within each block the apical safety margin
and the treatment boundaries are defined using transverse
and longitudinal ultrasound images. Planning proceeds
stepwise from the apex to the bladder neck. Within each
step the corresponding transverse ultrasound image is used
to determine the number of target lesions, to adjust the
focal length to the anterior-posterior prostate diameter
and to define the distance from the rectal wall. The blocks
are planned with overlapping target lesions. The conduct of
the procedure is automated and follows the plan accurately
[11].
2.4. Data acquisition
All statistical analysis was performed using StataSE v.13
(StataCorp LP, College Station, USA). For the purposes of
this retrospective study, patient characteristics and treat-
ment data were analyzed using prospectively collected
data of an Access database (since 2002) and the individual
treatment protocols. Patients were stratified into risk cat-
egories of tumor recurrence according to D’Amico et al. [5].
Criteria for the high-risk category were modified to include
patients with pathological stages cT3A and cT3B (TNM
2002). Treatment protocols provided detailed information
on the conduct of therapy with each procedure, including
the block strategy (number of treated blocks) and the type
of approach. We distinguished between a standard
approach, following exactly the pre-plan, and an approach
with adjustments of the plan to varying treatment condi-
tions. Adjustments, made either along the anterior-
posterior, cranio-caudal or latero-lateral prostate axis,
included the targeting of additional areas and modifications
in the length (reduction, extension) of the planned treat-
ment blocks. The protocols were also assessed for records
of prostate edema and patient movement. In patients with
prostate edema the shift in prostate height and/or rec-
toprostatic distance was estimated by comparing ultra-
sound images taken at the beginning and the end of
treatment near the mid-prostate. Measurements were
made using ImageJ image processing software [12].
For this study all available postoperative PSA values
were analyzed, which were either assessed in our clinic or
by the referring urologists. Biochemical relapse was defined
as PSA nadir þ1.2 ng/mL (Stuttgart definition [13]). Follow-
up period was defined as the interval between HIFU treat-
ment and the last available PSA values or death.
2.5. Statistical analysis
Patient characteristics and treatment variables (prostate
measurements, conduct of therapy) were summarized in
frequency tables, cross-tabulated with subgroups, by
Ablatherm HIFU devices, occurrence of prostate edema,
and patient movement. Categorical variables were
expressed as percentages and compared using Fisher’s
exact test. Quantitative variables were reported as median
and interquartile range (IQR) and compared with the
ManneWhitney U-test. The Cox regression model was used
in the univariate and multivariate analysis of the prognosticrelevance of preoperative and intraoperative factors of
biochemical progression. Backward elimination was used
and only the final model is given. The KaplaneMeier
method was used to construct survival curves, which were
compared using the log-rank test. A p-value <0.05 was
considered statistically significant.
3. Results
Totally 327 consecutive patients underwent a single ses-
sion of whole-gland HIFU therapy between December 2002
and December 2010. Median (IQR) age was 70 (66.5e74.0)
years. Baseline patient characteristics are summarized in
Table 1. The number of patients treated with the HIFU
devices A1 and A2 were 139 (42.5%) and 188 (57.5%),
respectively. In all, 112 (34.2%) men received ADT prior to
HIFU for a median (interquartile range, IQR) duration of
2.4 (1.3e5.6) months. Two hundred and sixty-four (80.7%)
patients with enlarged prostate glands (ante-
rioreposterior diameter >3 cm [TRUS]) underwent pro-
cedures to reduce the prostate size (TURP, n Z 258;
adenomectomy, n Z 6). In the post-surgery group, the
median (IQR) prostate volume at the time of HIFU treat-
ment was lower (17 [13e21] mL) than in the group without
surgery (21 [16e24] mL) (p Z 0.001).
Table 2 summarizes the treatment data of the whole
study population and of subgroups, by generations of HIFU
devices, occurrence of prostate edema, and patient
movement, respectively. In general, prostate volumes had
been reduced sufficiently by previous surgery to ensure that
the prostate height (pre-plan) corresponded to the limited
length of the ultrasound focus (26 mm) and anterior pros-
tate margins were exposed to HIFU. With most patients a
2-block-strategy and standard approach was used. In 93
(28.4%) men, the operator decided for adjustments during
the procedure, either ablation of additional areas (nZ 51)
or modifications in the length of the treatment blocks
(n Z 42).
With the A1 device, HIFU was more often delivered using
a 3-to-4-block-strategy and the operator decided more often
for adjustments, which explains the higher number of
elementary lesions, the higher treatment volume (computed
sum of single lesion volumes) and the longer treatment
duration compared with that seen for the A2 device.
Similarly, in 43 (13.1%) patients with prostate edema,
the therapy conducted was more extensive than that in the
remainder (Table 2). The measured shift in prostate height
was a median (IQR) of 5.2 (3.6e7.3) mm and the prosta-
torectal shift was 3.6 (0.4e5.3) mm, indicating both pros-
tatic and periprostatic swelling. At midprostate, the
maximum diameter between the anterior prostate margin
and the rectal wall was amedian (IQR) of 36.9 (33.3e38.5) mm
and the anterior gap not treatable by HIFU due to limited
penetration depth of HIFU was 6.6 (4.3e8.6) mm. These
patients exhibited a significantly higher prostate volume
and height at pre-plan (Table 2). Moreover, 18.7% (21/
112) of patients with previous ADT and 10.2% (22/215)
without ADT exhibited prostate edema (p Z 0.038).
Conversely, edema occured in 9.5% (25/264) of patients
with previous prostate surgery and in 28.6% (18/63)
without surgery (p < 0.001).
Table 1 Baseline characteristics in 327 patients and in subgroups by Ablatherm HIFU devices A1 and A2.
Characteristics Total (n Z 327) Ablatherm HIFU devices p-value
Device A1a (n Z 139) Device A2a (n Z 188)
Age (years) 70 (66.5e74.0) 71 (66.5e75.0) 70 (66.7e74.0) 0.46
Prostate volume at visit (mL) 28.0 (20.0e36.8) 23.0 (17.0e31.0) 31.1 (23.3e40.0) <0.001
PSA at diagnosis (ng/mL) 7.1 (5.0e11.0) 7.2 (4.8e13.2) 7.1 (5.1e10.5) 0.58
Clinical tumor stagesb 0.72
T1 185 (56.6) 77 (55.4) 108 (57.4)
T2 120 (36.7) 54 (38.8) 66 (35.1)
T3 22 (6.7) 8 (5.8) 14 (7.4)
Gleason sum 0.066
6 202 (61.8) 90 (64.7) 112 (59.6)
7 90 (27.5) 30 (21.6) 60 (31.9)
8e10 35 (10.7) 19 (13.7) 16 (8.5)
Risk groupsc 0.115
Low 130 (39.8) 51 (36.7) 79 (42.0)
Intermediate 115 (35.2) 45 (32.4) 70 (37.2)
High 82 (25.1) 43 (30.9) 39 (20.7)
ADTd 112 (34.2) 67 (48.2) 45 (23.9) <0.001
Values are median (interquartile range) or n (%).
a A1 Z Ablatherm Maxis, A2 Z Ablatherm Integrated Imaging.
b TNM-classification 2002.
c Risk groups according to D’Amico et al. [5].
d Androgen deprivation therapy (preoperative).
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and required intraoperative adjustments of the procedure
more frequently (Table 2). Fifty-seven men exhibited
movements under spinal anesthesia and i.v. sedation due to
agitation or cough and six men moved under shallow gen-
eral anesthesia. The procedure was discontinued in four
men treated under spinal anesthesia and interrupted in the
remainder for the purpose of re-planning the procedure.
With only four patients lost during follow-up, biochem-
ical outcome data were available for 323 (98.8%) men.
Median (IQR) follow-up was 51.2 (36.6e80.4) months with
significant differences between the two generations of
HIFU devices (84.8 [67.0e92.8] vs. 42.3 [32.4e51.2]
months; p < 0.001) according to the later introduction of
the A2 device.
Overall, 77 (23.8%) men exhibited biochemical relapse.
Median (IQR) time to failure was 18.2 (6.5e32.7) months.
Higher preoperative risk categories, the PSA value (at
diagnosis), the A2 HIFU device and prostate edema were
predictive factors of biochemical failure (Table 3), while
multivariate analysis eliminated patient age, TNM-stages,
Gleason sum, ADT, prostate volume (pre-plan), conduct of
therapy (block strategies, type of approach), and spinal
anesthesia as independent predictors (backward elimina-
tion). Notably, patient movements were neither a
predictor in univariate analysis nor in multivariate
analysis.
The outcomes with both HIFU devices were further
analyzed with a follow-up truncated to 50 months in order
to adjust for different monitoring periods. The A2 device
was associated with a decreased risk of biochemical failure
(HR [95%CI]: 0.415 [0.253e0.672]). The biochemical failure-
free survival rates with devices A1 and A2 were 70.3% and
82.3%, respectively (p < 0.001) (Fig. 1).4. Discussion
This study found that biochemical relapse is not excluded
even if whole-gland treatment is performed to ensure
complete eradication of localized PCa. The overall
biochemical failure rate was 23.8%. Higher D’Amico risk
stages proved to be strong predictors of adverse biochem-
ical outcomes, as in previous reports [2e4]. However, HIFU
efficacy was not merely dependent on tumor characteris-
tics, but also on treatment-related factors.
In our hands, single-session HIFU treatment proved to be
more efficacious with the latest HIFU device than with the
older model, as indicated by a decreased risk of biochem-
ical recurrence. The differing results with both devices
were not biased by different distributions of preoperative
D’Amico risk stages or differing PSA levels at diagnosis.
Although differences in the conduct of therapy (block
strategies, type of approach) and administration of short-
term preoperative ADT were associated with the use of
both devices, the changing practice in treating patients
over time was not responsible for the decreasing
biochemical failure rate, since these factors were not
related to the outcomes on multivariate analysis. More
likely, the increasing efficacy of HIFU treatment originated
in technical advances.
By contrast to our results, the latest Ablatherm device
did not prove to be more efficacious in a recent study by
Crouzet et al. [2]. However, their study included patients
who received repeat HIFU treatments with retreatment
rates differing between both devices. In addition, the
Phoenix definition (PSA nadir þ 2 ng/mL) of PSA relapse was
used, originally designed to monitor biochemical response
following radiotherapy [14]. We decided to focus on the
efficacy of single-session HIFU treatment as in an earlier
Table 2 Prostate measurements (pre-plan) and conduct of treatment in the whole study population and in subgroups, by different Ablatherm HIFU devices, occurrence of
prostate edema, or patient movement.









18 (14.0e22.0) 19 (13.5e24.0) 18 (14.0e21.0) 0.033 21 (18.0e24.5) 17 (13.0e21.0) 0.001 18 (13.0e21.6) 18 (14.0e22.0) 0.985
Prostate
height (mm)
22 (19.0e25.0) 23 (20.0e25.0) 20 (18.0e24.0) <0.001 24 (20.5e25.8) 21 (18.0e24.0) 0.006 21 (18.0e24.0) 21 (18.0e24.0) 0.877
Block strategy <0.001 <0.001 0.480
2 blocks 194 (59.3) 63 (45.3) 131 (69.7) 17 (39.5) 177 (62.3) 35 (55.6) 159 (60.2)
3 blocks 128 (39.1) 71 (51.1) 57 (30.3) 22 (51.2) 106 (37.3) 28 (44.4) 100 (37.9)
4 blocks 5 (1.5) 5 (3.6) 0 4 (9.3) 1 (0.4) 0 5 (1.9)
Approach <0.001 0.046 0.031
Standard 234 (71.6) 83 (59.7) 151 (80.3) 25 (58.1) 209 (73.6) 38 (60.3) 196 (74.2)
With adjustments 93 (28.4) 56 (40.3) 37 (19.7) 18 (41.9) 75 (26.4) 25 (39.7) 68 (25.8)
Metric treatment data
Duration (min) 145 (125e175) 165 (135e200) 135 (120e155) <0.001 160 (135e190) 145 (121e170) 0.006 150 (130e180) 145 (120e170) 0.090
Lesions (No.) 589 (505e676) 629 (505e759) 571 (504e644) 0.008 635 (550e697) 580 (497e668) 0.024 598 (516e701) 586 (500e670) 0.463
Tx-volume (mL)b 37.9 (31.0e44.0) 40.5 (32.0e50.2) 36 (30.0e41.0) <0.001 42 (36.5e46.5) 37 (31.0e43.0) 0.003 38 (31.0e45.5) 37 (31.0e44.0) 0.659
Tx-ratioc 2.1 (1.8e2.6) 2.1 (1.7e2.8) 2.1 (1.8e2.4) 0.864 2 (1.7e2.5) 2.1 (1.8e2.6) 0.264 2.1 (1.7e2.7) 2.1 (1.7e2.5) 0.594
Anesthesia 0.039 0.590 1.000
Spinal 295 (90.2) 131 (94.2) 164 (87.2) 38 (88.4) 257 (90.5) 57 (90.5) 239 (90.2)
General 32 (9.8) 8 (5.8) 24 (12.8) 5 (11.6) 27 (9.5) 6 (9.5) 26 (9.8)
Values are median (interquartile range) or n (%).
a A1 Z Ablatherm Maxis, A2 Z Ablatherm Integrated Imaging.
b Treatment-volume (computed sum of single lesion volumes).












Figure 1 KaplaneMeier estimates of biochemical failure-
free survival at 50 months in 323 patients following single-
session HIFU treatment (whole-gland therapy) of localized
prostate cancer, by different generations of Ablatherm device.
Device A1, Ablatherm Maxis; Device A2, Ablatherm Integrated
Imaging. A1 vs. A2, p < 0.001.
Table 3 Univariate and multivariate analysis (final model) of preoperative and intraoperative biochemical failure predictors.
Variable Univariate analysis Multivariate analysis (final model)
HR 95%CI p-value HR 95%CI p-value
Preoperative
Patients’ age 1.01 0.97e1.06 0.468 e
PSA at diagnosis 1.04 1.03e1.05 <0.001 1.03 1.01e1.04 <0.001
Clinical tumor stagea
T1-2A 1
T2B 1.93 1.23e3.05 <0.001 e
Gleason sum 1.42 1.17e1.72 <0.001 e
Risk group (D’Amico)
Low 1 1
Intermediate/high 4.62 2.50e8.54 <0.001 3.45 1.82e6.52 <0.001
ADTb 0.38 0.24e0.59 <0.001 e
Intraoperative
Prostate volumec 0.99 0.97e1.03 0.952 e
HIFU deviced
A1 1 1
A2 0.43 0.27e0.70 <0.001 0.51 0.32e0.83 0.007
Block strategy
2 blocks 1
>2 blocks 1.26 0.81e1.95 0.302 e
Approach
With adjustments 1
Standard 0.57 0.36e0.89 0.014 e
Prostate edema 2.24 1.33e3.75 <0.001 1.80 1.07e3.04 0.027
Patients movements 1.13 0.65e1.95 0.661 e
Anesthesia
General 1
Spinal 4.03 0.99e16.44 0.052 e
HR, hazard ratio; CI, confidential interval.
a TNM classification 2002.
b Androgen deprivation therapy (preoperative).
c Prostate volume at HIFU treatment (pre-plan).
d A1 Z Ablatherm Maxis, A2 Z Ablatherm Integrated Imaging.
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(PSA nadir þ 1.2 ng/mL) was selected as it provides a more
specific evaluation of HIFU outcome [13], which is mean-
ingful for comparisons between HIFU devices.
Heat-induced prostate edema occurred in a small pro-
portion of patients (13.1%) and was an independent pre-
dictor of HIFU outcomes. Prostate swelling was first
described by Shoji et al. [16] in patients without previous
ADT or TURP treated with the alternative Sonablate HIFU
device (Focus surgery, Indianapolis, IN, USA). We demon-
strate that edema may not only involve the prostate gland
but also the periprostatic tissue, then widening the recto-
prostatic space. Both effects contribute to an enlarged
distance between the anterior prostate margin and the
rectal wall which may result in an anterior gap of untreated
tissue. In these cases, HIFU may fail due to the limited
penetration depth of the ultrasound. In contrast to the
findings of Shoji et al. [16], prostate glands with edema had
a higher volume and AP-diameter on pre-plan. Moreover,
previous ADT might have an adverse effect, while previous
TURP reduces the risk of swelling. This can be explained
consistently by an imbalance between release and drainage
of intraprostatic fluids after tissue destruction, which is
52 D. Pfeiffer et al.pronounced in larger glands and even more accentuated by
an ADT-induced involution of the prostatic vasculature
[17,18]. TURP provides additional drainage via the prostate
cavity instead.
This is the first report on unintentional patient move-
ments during HIFU therapy. Movements occurred in 19% of
the men and are a challenge to the operator. Most move-
ments were noted under spinal anesthesia and supplemen-
tary i.v. sedation which was the predominant anesthetic
modality, as also in other clinics [3,19]. Accordingly, this
regimen is not ideal to provide both analgesia and immobi-
lization in all patients. As shown, movements may enforce a
discontinuation of the procedure, although treatment could
be completed in most patients after adjustments for pros-
tate shifts. Most importantly, movements were not an in-
dependent predictor of biochemical outcome, suggesting
that movements during HIFU procedures could be compen-
sated sufficiently by the operator to avoid untreated gaps
within the prostate tissue.
This study has limitations according to its retrospective
nature. The follow-up period with the latest HIFU device
was still too short to verify a definite advantage over the
older model and more studies with a longer follow-up are
needed in order to confirm the present results using the
same criteria of PSA relapse. The biochemical outcomes
were used as a surrogate parameter for treatment efficacy
whereas local control was not analyzed.
5. Conclusion
HIFU efficacy is not only dependent on preoperative tumor
characteristics, but also on treatment-related factors. Our
data support the preliminary estimate that the efficacy
increases with the technically advanced latest HIFU device.
Prostate edema might adversely affect the outcome.Conflicts of interest
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